Sentences with phrase «direct acting antiviral»

Access to affordable HCV direct acting antiviral regimens for people who inject drugs should be a major focus to harness this potential prevention capacity.»

These first - generation direct - acting antivirals are the first of many direct acting antiviral drugs which will revolutionise treatment for HCV patients, including those who failed to respond to previous therapies.

The research team is calling for the government to subsidise a new therapy which has high cure rates, known as direct acting antiviral (DAA) therapy.

Before deciding on a treatment, your doctor will take into account the genotype (strain) of your hepatitis C. Treatment for hepatitis C now relies on medicines called direct acting antivirals (DAAs), which stop the virus from reproducing.

Not exact matches

As treatments for HCV have evolved, genotype 3 patients have become the most difficult subgroup of patients to cure.1 Although there have been recent advances in direct - acting antiviral therapies for HCV genotype 1, genotype 3 remains a challenge and is a highly prevalent strain of the infection globally, with a particularly high concentration of cases in Asia.1

While the once - daily dosing, low side - effects profile, and shortened treatment duration of interferon - free direct - acting antivirals are ideal for injection drug users, most trials of these therapies for HCV have excluded persons with recent injection drug use.

Treatment options for HCV genotype 1 are evolving rapidly from interferon - based regimens to all - oral, direct - acting antiviral only regimens.

In two studies appearing in the May 5 issue of JAMA, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of the direct - acting - antiviral drugs daclatasvir, asunaprevir, and beclabuvir.

But in the last several years, more effective drugs, called direct - acting antivirals, have been approved for use.

Direct - acting antiviral prophylaxis in kidney transplantation from Hepatitis C virus - infected donors to noninfected recipients: an open - label nonrandomized trial.

Direct - acting antivirals can control hepatitis C and show promise of long - term cure, but viral mutation to drug resistance is a concern with prolonged use of these drugs.

A new HCV infection is effectively treated with direct - acting antiviral drugs, but the researchers say a preventive vaccine is needed to control what they call an HCV pandemic because as many as 50 percent of people infected are unaware that they carry the virus, putting others at risk of infection.

While direct - acting antivirals have been used to treat and cure adult patients with HCV, until now children have been mainly treated for 24 to 48 weeks with pegylated interferon plus ribavirin (RBV), an older treatment which causes severe side effects.

«Direct - acting antivirals have transformed the treatment of adults with chronic HCV, however, studies of these new therapies in children are required,» said Dr Karen Murray, University of Washington School of Medicine and Seattle Children's, Seattle, United States, and lead author of the study.

«These data establish the use of the oral direct - acting antivirals as an important treatment option in HCV - infected children aged six to 11 years old.»

Ongoing clinical trials with 20 other so - called direct - acting antivirals have had even more impressive results against HCV, and researchers have high hopes that curing this devastating disease will become routine — but only if people know they are infected and seek treatment.

Interim data presented today at The International Liver Congress 2015 from the HCV - TARGET study show that all - oral, direct - acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients...